Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation

The article favors Johnson & Johnson over Pfizer, citing J&J’s 7.4% expected 2026 sales growth, 7.0% EPS growth, and 23.7% year-to-date share gain versus Pfizer’s 0.2% expected sales decline, 7.5% EPS decline, and 11.7% share gain. J&J reported $49.4 billion in first-half 2026 revenue and targets more than $100 billion for the year, while Pfizer faces an estimated $1.1 billion 2026 revenue hit from patent expirations and continued COVID-product declines. Pfizer trades at a lower 9.41 forward P/E and offers a 6.2% dividend yield, compared with J&J’s 20.69 forward P/E and 2.1% yield; both carry a Zacks Rank of Hold.

Analysis

The key divergence is not simply “growth versus yield”: J&J’s premium assumes new launches can sustain growth through Stelara erosion, while Pfizer’s discount reflects uncertainty that launches and acquisitions can replace COVID-product declines and later patent losses. J&J’s strong relative share performance makes the bar higher; recent consensus EPS trims are a warning that confidence in the growth path is not yet translating uniformly into estimates. Conversely, Pfizer’s modest estimate upgrades suggest expectations may be stabilizing, but they do not resolve the 2026–30 replacement-product gap.

For J&J, the near-term test is whether Stelara erosion is offset by newer medicines and whether MedTech recovers; a miss there could compress an already elevated multiple. Talc litigation remains a discrete headline risk until resolution is definitive. Over 6–18 months, launch uptake and the timing of Opsumit and Simponi competition matter more than aspirational peak-sales claims.

Pfizer’s obesity program is an option, not a near-term earnings bridge: phase III execution and 2028 approval ambitions leave substantial time and competitive risk versus Eli Lilly and Novo Nordisk. Oncology pipeline breadth also needs proof through pivotal data, not study count. A contrarian angle is that Pfizer’s improved estimate revisions may be underappreciated, but the high yield alone is not evidence the dividend is secure through the patent cycle. The article supports a quality preference for J&J, but not an aggressive chase after its outperformance.

Key Decisions for Investors

• Prefer JNJ to PFE on a 6–18 month quality basis, but add only on weakness rather than chasing the YTD rerating. Reassess if Innovative Medicine growth decelerates materially or MedTech fails to improve in the second half.
• Keep PFE underweight versus JNJ; treat its low multiple and yield as compensation for patent and replacement-product uncertainty, not a catalyst. Revisit if launch/acquired-product growth persists and guidance or consensus revisions turn meaningfully higher.
• For a relative-value expression, consider a modest long JNJ / short PFE pair, sized for the possibility that JNJ’s premium compresses. Avoid initiating at stretched relative performance; exit or reduce if JNJ’s estimate revisions stabilize upward while PFE’s weaken further.
• Monitor Stelara erosion and JNJ litigation milestones; for PFE, track COVID-product declines, LOE offsets, and pivotal data for berobenatide and PF-08634404. These are the evidence points that could invalidate the relative-quality thesis.